Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress | ||||||||||
By: GlobeNewswire - 20 Mar 2024 | Back to overview list |
|||||||||
VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24. He will discuss Nusano’s plans to supply commercial-scale lutetium-177 beginning in early 2025 and to make the short-lived radioisotope, astatine-211, viable for therapeutic use. The company presentation is available in advance of the conference at Nusano.com. Nusano leadership will also be available for 1-on-1 meetings with conference attendees. To request a meeting, please email info@nusano.com. “Nusano is bringing our commercial-scale, proprietary technology online to support cancer patients, stabilize supply chains and enable innovation,” said Greg Moffitt, Director of Target Development at Nusano. “We are on track to provide lutetium-177 and actinium-225 in 2025 and look forward to driving the next wave of radiotherapeutics by delivering abundant supplies of a wide variety of highly promising radioisotopes.”
About Nusano Contacts: Media: Scott Larrivee, Nusano, 608-345-6629, scott.larrivee@nusano.com Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, jallaire@lifesciadvisors.com |
||||||||||
|
||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |